APHINITY (BIG 04-11/ BO25126/ TOC4939G)
Clinical Trial Program
A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HER2-positive primary breast cancer.
Phase III
Status
Follow up
Tumour subtype:
HER2+
Scenario
Adjuvant
SPONSOR
COLLABORATORS
PRINCIPAL INVESTIGATORS
Gunter von Minckwitz, MD, PhD (German Breast Group (GBG))
Jose Baselga, MD, PhD (MGH Cancer Center)
José Bines, MD (Instituto Nacional de Câncer, Brazil)
Sites
HOSPITAL ARNAU DE VILANOVA DE VALENCIA, HOSPITAL CLÍNICO UNIV. SANTIAGO DE COMPOSTELA, HOSPITAL CLÍNICO UNIVERSITARIO DE VALENCIA, HOSPITAL SON ESPASES, HOSPITAL SON LLATZER, HOSPITAL UNIVERSITARI ARNAU DE VILANOVA DE LLEIDA, HOSPITAL UNIVERSITARI VALL D’HEBRON, HOSPITAL UNIVERSITARIO 12 DE OCTUBRE, HOSPITAL UNIVERSITARIO VIRGEN DE LA MACARENA
